# Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI

> **NCT00229515** · PHASE4 · UNKNOWN · sponsor: **Marco Valgimigli** · enrollment: 744 (actual)

## Conditions studied

- Myocardial Infarction

## Interventions

- **OTHER:** abciximab followed by implantation of bare metal stent
- **OTHER:** abciximab and Sirolimus eluting stent
- **OTHER:** tirofiban and bare metal stent
- **OTHER:** tirofiban and sirolimus-eluting stent

## Key facts

- **NCT ID:** NCT00229515
- **Lead sponsor:** Marco Valgimigli
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-11
- **Primary completion:** 2007-04
- **Final completion:** 2012-03
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2011-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00229515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00229515, "Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00229515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*